KalVista’s Novel DME Approach Moves To Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.